Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Background. The current standard treatment for transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM) consists of quadruplet induction with proteasome inhibitors, immunomodulatory agents, dexamethasone and anti-CD38 monoclonal antibody followed by high-dose melphalan an...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2023-11, Vol.142 (Supplement 1), p.4-4
Main Authors: Gay, Francesca, Roeloffzen, Wilfried, Dimopoulos, Meletios A., Rosiñol, Laura, van der Klift, Marjolein, Mina, Roberto, Rocafiguera, Albert Oriol, Katodritou, Eirini, Wu, Ka Lung, Rodriguez Otero, Paula, Hajek, Roman, Antonioli, Elisabetta, van Duin, Mark, D'Agostino, Mattia, Martinez-Lopez, Joaquin, van Leeuwen-Segarceanu, Elena M., Tacchetti, Paola, van de Donk, Niels W.C.J., Weisel, Katja, Pour, Luděk, Radocha, Jakub, Belotti, Angelo, Schjesvold, Fredrik, Bladé, Joan, Einsele, Hermann, Sonneveld, Pieter, Boccadoro, Mario, Broijl, Annemiek
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. The current standard treatment for transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM) consists of quadruplet induction with proteasome inhibitors, immunomodulatory agents, dexamethasone and anti-CD38 monoclonal antibody followed by high-dose melphalan and autologous stem-cell transplant (MEL200-ASCT), with subsequent consolidation. The phase III IsKia trial assessed efficacy and safety of isatuximab-carfilzomib-lenalidomide-dexamethasone (IsaKRd) as pre-ASCT induction and post-ASCT consolidation vs KRd. Methods. TE NDMM pts aged
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2023-177546